Legal Representation
Attorney
                                            Peter J. Willsey
                                        USPTO Deadlines
                                Next Deadline
                            
                            
                                    
                                        
                                        35 days remaining
                                    
                            
                        Statement of Use Due - Extension 3 Granted
                                    
                                    Due Date
                                
                                
                                    December 05, 2025
                                
                            
                                        
                                        Extension Available
                                    
                                    
                                        Until December 05, 2024
                                    
                                Application History
33 events| Date | Code | Type | Description | Documents | 
|---|---|---|---|---|
| Sep 20, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... | 
| Sep 19, 2025 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... | 
| Sep 19, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... | 
| Sep 19, 2025 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... | 
| Sep 9, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... | 
| Sep 9, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... | 
| Sep 9, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... | 
| Sep 9, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... | 
| Sep 9, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... | 
| Mar 10, 2025 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... | 
| Mar 10, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... | 
| Mar 10, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... | 
| Mar 10, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... | 
| Feb 19, 2025 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... | 
| Feb 19, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... | 
| Feb 18, 2025 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... | 
| Feb 18, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... | 
| Sep 16, 2024 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... | 
| Sep 16, 2024 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... | 
| Sep 16, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... | 
| Sep 16, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... | 
| Jan 19, 2024 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... | 
| Jan 17, 2024 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... | 
| Jan 17, 2024 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... | 
| Jan 17, 2024 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... | 
| Dec 5, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... | 
| Oct 10, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... | 
| Oct 10, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... | 
| Sep 20, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... | 
| Sep 1, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... | 
| Aug 30, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... | 
| Feb 26, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... | 
| Feb 10, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... | 
Detailed Classifications
                                                Class 005
                                            
                                        Pharmaceutical preparations for the treatment of sarcoidosis, interstitial lung disease, pulmonary fibrosis, and idiopathic pulmonary fibrosis; Pharmaceutical preparations for the treatment of pulmonary hypertension, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with lung disease, pulmonary hypertension associated with interstitial lung disease (PH-ILD), pulmonary hypertension associated with chronic obstructive pulmonary disease, portopulmonary hypertension, pulmonary hypertension associated with sleep-related breathing disorders, pulmonary hypertension associated with chronic thrombotic and embolic disease, and pulmonary hypertension secondary to hematologic, metabolic, renal, granulomatous, or fibrotic disorders
                                        Classification
                                            
                                            International Classes
                                        
                                        
                                                    005